These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24643319)

  • 1. Hepatic sinusoidal obstruction syndrome caused by herbal medicine: CT and MRI features.
    Zhou H; Wang YX; Lou HY; Xu XJ; Zhang MM
    Korean J Radiol; 2014; 15(2):218-25. PubMed ID: 24643319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome.
    Kan X; Ye J; Rong X; Lu Z; Li X; Wang Y; Yang L; Xu K; Song Y; Hou X
    Sci Rep; 2016 Nov; 6():37998. PubMed ID: 27897243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study.
    Liu F; Rong X; Guo H; Xu D; Liu C; Meng L; Yang X; Guo T; Kan X; Song Y
    BMC Gastroenterol; 2020 Feb; 20(1):30. PubMed ID: 32019495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.
    Yang XQ; Ye J; Li X; Li Q; Song YH
    World J Gastroenterol; 2019 Jul; 25(28):3753-3763. PubMed ID: 31391770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gynura Segetum Related Hepatic Sinusoidal Obstruction Syndrome: A Liver Disease with High Mortality and Misdiagnosis Rate.
    Ou P; Liu X; Tang Z; Hou Z; Liu L; Liu J; Zhou S; Fang Z; Sun K; Chen Y; Chen X; Li Y; Chen J
    Curr Pharm Des; 2019; 25(35):3762-3768. PubMed ID: 31589115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tusanqi and hepatic sinusoidal obstruction syndrome.
    Wang JY; Gao H
    J Dig Dis; 2014 Mar; 15(3):105-7. PubMed ID: 24528632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.
    Gao H; Li N; Wang JY; Zhang SC; Lin G
    J Dig Dis; 2012 Jan; 13(1):33-9. PubMed ID: 22188914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function.
    Guo T; Li X; Yang X; Kong X; Liu H; Bai T; Xu K; Ye J; Song Y
    Sci Rep; 2019 Feb; 9(1):1231. PubMed ID: 30718698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.
    Lin G; Wang JY; Li N; Li M; Gao H; Ji Y; Zhang F; Wang H; Zhou Y; Ye Y; Xu HX; Zheng J
    J Hepatol; 2011 Apr; 54(4):666-73. PubMed ID: 21146894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.
    Gao H; Ruan JQ; Chen J; Li N; Ke CQ; Ye Y; Lin G; Wang JY
    Drug Des Devel Ther; 2015; 9():4861-8. PubMed ID: 26346783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
    Zhuge Y; Liu Y; Xie W; Zou X; Xu J; Wang J;
    J Gastroenterol Hepatol; 2019 Apr; 34(4):634-642. PubMed ID: 30669184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of MMP-9 in hepatic sinusoidal obstruction syndrome induced by Gynura segetum.
    Yu XZ; Ji T; Bai XL; Liang L; Wang LY; Chen W; Liang TB
    J Zhejiang Univ Sci B; 2013 Jan; 14(1):68-75. PubMed ID: 23303633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gynura segetum induces hepatic sinusoidal obstruction syndrome in a child: A case report.
    Zheng Q; Zhang H
    Medicine (Baltimore); 2024 Mar; 103(11):e37341. PubMed ID: 38489699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Analysis of CT Images in Patients with Pyrrolizidine Alkaloid-Induced Sinusoidal Obstruction Syndrome.
    Wang C; Wu X; Xie W; Ren X; Zhang W; Xu J
    Sci Rep; 2019 Feb; 9(1):2179. PubMed ID: 30778132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic sinusoidal obstruction syndrome caused by the ingestion of
    Cen P; Ding J; Jin J
    J Int Med Res; 2021 Apr; 49(4):300060520980649. PubMed ID: 33845617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
    Wang X; Zhang W; Zhang M; Zhang F; Xiao J; Yin Q; Han H; Li T; Lin G; Zhuge Y
    Hepatol Int; 2022 Jun; 16(3):669-679. PubMed ID: 35023026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gynura Rhizoma containing pyrrolizidine alkaloids induces the hepatic sinusoidal obstruction syndrome in mice via upregulating fibrosis-related factors.
    Zhang F; Zhou Y; Yang X; Xiong AZ; Wang ZT; Yang L
    Acta Pharmacol Sin; 2019 Jun; 40(6):781-789. PubMed ID: 30367152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative CT assessment by histogram and volume ratio in pyrrolizidines alkaloids-induced hepatic sinusoidal obstruction syndrome.
    Yang X; Lei P; Song Y; Fei Z; Ai Y; Shang H; Bai T; Ye J; Li X
    Eur J Radiol; 2021 May; 138():109632. PubMed ID: 33711570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans.
    Yang M; Ruan J; Gao H; Li N; Ma J; Xue J; Ye Y; Fu PP; Wang J; Lin G
    Arch Toxicol; 2017 Dec; 91(12):3913-3925. PubMed ID: 28620673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT Features of Hepatic Veno-occlusive Disease: A Meta-analysis.
    Yang S; Wu J; Lei S
    Acad Radiol; 2018 Mar; 25(3):328-337. PubMed ID: 29191686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.